Redeye returns following IRLAB's Q2 report and recent clinical progress. We reiterate our positive stance to the company and look forward to an exciting H2.
ANNONS
Redeye returns following IRLAB's Q2 report and recent clinical progress. We reiterate our positive stance to the company and look forward to an exciting H2.